Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Get Free Report) EVP Kevin Joseph Fitzgerald sold 1,198 shares of Alnylam Pharmaceuticals stock in a transaction that occurred on Tuesday, June 25th. The shares were sold at an average price of $230.99, for a total value of $276,726.02. Following the sale, the executive vice president now directly owns 14,181 shares in the company, valued at approximately $3,275,669.19. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink.
Alnylam Pharmaceuticals Trading Up 2.1 %
Shares of NASDAQ:ALNY opened at $245.17 on Thursday. The stock has a market capitalization of $31.01 billion, a PE ratio of -91.48 and a beta of 0.30. Alnylam Pharmaceuticals, Inc. has a 1 year low of $141.98 and a 1 year high of $249.33. The firm has a fifty day moving average price of $155.86 and a 200 day moving average price of $163.65.
Alnylam Pharmaceuticals (NASDAQ:ALNY - Get Free Report) last issued its quarterly earnings data on Thursday, May 2nd. The biopharmaceutical company reported ($0.52) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.75) by $0.23. The business had revenue of $494.33 million during the quarter, compared to the consensus estimate of $428.01 million. The company's revenue for the quarter was up 54.8% on a year-over-year basis. During the same quarter in the prior year, the company posted ($1.40) earnings per share. On average, sell-side analysts forecast that Alnylam Pharmaceuticals, Inc. will post -3.75 earnings per share for the current fiscal year.
Wall Street Analysts Forecast Growth
Biden out June 13; replacement chosen?
From Paradigm Press | Ad
On November 16, 2023…
Joe Biden accidentally revealed the name of the candidate…
Who will replace him in the 2024 presidential election.
See who it is HERE.
A number of research firms recently commented on ALNY. TD Cowen raised their price objective on shares of Alnylam Pharmaceuticals from $260.00 to $282.00 and gave the company a "buy" rating in a research note on Tuesday. HC Wainwright reiterated a "buy" rating and set a $400.00 price objective on shares of Alnylam Pharmaceuticals in a research note on Monday. Canaccord Genuity Group reiterated a "buy" rating and set a $283.00 price objective on shares of Alnylam Pharmaceuticals in a research note on Friday, June 21st. Citigroup lifted their price target on shares of Alnylam Pharmaceuticals from $227.00 to $291.00 and gave the stock a "buy" rating in a research report on Tuesday. Finally, Chardan Capital restated a "buy" rating and issued a $225.00 price target on shares of Alnylam Pharmaceuticals in a research report on Friday, May 3rd. Eight equities research analysts have rated the stock with a hold rating and sixteen have issued a buy rating to the stock. According to data from MarketBeat.com, Alnylam Pharmaceuticals currently has an average rating of "Moderate Buy" and an average target price of $245.14.
View Our Latest Analysis on Alnylam Pharmaceuticals
Institutional Investors Weigh In On Alnylam Pharmaceuticals
Large investors have recently bought and sold shares of the business. Vanguard Group Inc. boosted its holdings in Alnylam Pharmaceuticals by 0.4% during the first quarter. Vanguard Group Inc. now owns 11,994,261 shares of the biopharmaceutical company's stock valued at $1,792,542,000 after acquiring an additional 50,366 shares during the period. Wellington Management Group LLP boosted its holdings in Alnylam Pharmaceuticals by 6.0% during the third quarter. Wellington Management Group LLP now owns 6,431,814 shares of the biopharmaceutical company's stock valued at $1,139,074,000 after acquiring an additional 364,021 shares during the period. Price T Rowe Associates Inc. MD boosted its holdings in Alnylam Pharmaceuticals by 5.8% during the first quarter. Price T Rowe Associates Inc. MD now owns 3,685,753 shares of the biopharmaceutical company's stock valued at $550,837,000 after acquiring an additional 201,784 shares during the period. Capital International Investors boosted its holdings in Alnylam Pharmaceuticals by 1.8% during the first quarter. Capital International Investors now owns 3,651,217 shares of the biopharmaceutical company's stock valued at $545,674,000 after acquiring an additional 64,560 shares during the period. Finally, Capital Research Global Investors raised its position in shares of Alnylam Pharmaceuticals by 7.3% during the first quarter. Capital Research Global Investors now owns 3,144,987 shares of the biopharmaceutical company's stock valued at $470,018,000 after buying an additional 214,908 shares during the last quarter. 92.97% of the stock is currently owned by institutional investors.
Alnylam Pharmaceuticals Company Profile
(
Get Free Report)
Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
